-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Halozyme Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $163M, a 84.9% increase year-over-year.
- Halozyme Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $477M, a 53.4% increase year-over-year.
- Halozyme Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $338M, a 26.2% increase from 2022.
- Halozyme Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $268M, a 3.03% decline from 2021.
- Halozyme Therapeutics, Inc. annual Operating Income (Loss) for 2021 was $276M, a 91.3% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)